MLL-AF9 initiates transformation from fast-proliferating myeloid progenitors

Nat Commun. 2019 Dec 18;10(1):5767. doi: 10.1038/s41467-019-13666-5.

Abstract

Cancer is a hyper-proliferative disease. Whether the proliferative state originates from the cell-of-origin or emerges later remains difficult to resolve. By tracking de novo transformation from normal hematopoietic progenitors expressing an acute myeloid leukemia (AML) oncogene MLL-AF9, we reveal that the cell cycle rate heterogeneity among granulocyte-macrophage progenitors (GMPs) determines their probability of transformation. A fast cell cycle intrinsic to these progenitors provide permissiveness for transformation, with the fastest cycling 3% GMPs acquiring malignancy with near certainty. Molecularly, we propose that MLL-AF9 preserves gene expression of the cellular states in which it is expressed. As such, when expressed in the naturally-existing, rapidly-cycling immature myeloid progenitors, this cell state becomes perpetuated, yielding malignancy. In humans, high CCND1 expression predicts worse prognosis for MLL fusion AMLs. Our work elucidates one of the earliest steps toward malignancy and suggests that modifying the cycling state of the cell-of-origin could be a preventative approach against malignancy.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Cycle / drug effects
  • Cell Cycle / genetics
  • Cell Differentiation / drug effects
  • Cell Differentiation / genetics
  • Cell Proliferation / drug effects
  • Cell Proliferation / genetics
  • Cell Transformation, Neoplastic / drug effects
  • Cell Transformation, Neoplastic / genetics*
  • Cyclin D1 / metabolism
  • Disease Models, Animal
  • Female
  • Gene Expression Regulation, Leukemic*
  • Gene Knock-In Techniques
  • Humans
  • Kaplan-Meier Estimate
  • Leukemia, Myeloid, Acute / drug therapy
  • Leukemia, Myeloid, Acute / genetics*
  • Leukemia, Myeloid, Acute / mortality
  • Male
  • Mice, Transgenic
  • Myeloid Progenitor Cells / pathology*
  • Myeloid-Lymphoid Leukemia Protein / genetics*
  • Oncogene Proteins, Fusion / genetics*
  • Piperazines / administration & dosage
  • Primary Cell Culture
  • Prognosis
  • Pyridines / administration & dosage

Substances

  • CCND1 protein, human
  • MLL-AF9 fusion protein, human
  • Oncogene Proteins, Fusion
  • Piperazines
  • Pyridines
  • Cyclin D1
  • Myeloid-Lymphoid Leukemia Protein
  • palbociclib